22 completed, 6 terminated, 5 unknown, 4 recruiting. 43 Phase 1, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 43 | Completed 22, Terminated 6, Unknown 5, Recruiting 4, Withdrawn 4, Enrolling by invitation 1, Suspended 1 |
| Phase 2 | 21 | Completed 9, Terminated 5, Withdrawn 4, Recruiting 1, Suspended 1, Unknown 1 |
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis TRX103 - Non Infectious Uveitis | Phase 1 | Recruiting | Quan Dong Nguyen | 18 | 2026-03-18 | 2026-11-02 |
| A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants REGN7041 - Active Noninfectious Uveitis Affecting the Posterior Segment | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 1 | 2025-12-17 | 2026-08-17 |
| Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients DF-003 - ROSAH | Phase 1 | Recruiting | Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) | 12 | 2025-05-27 | 2026-06-05 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Recruiting | Chugai Pharmaceutical | 144 | 2024-08-19 | 2026-07-22 |
| Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study Laquinimod eye drops - Inflammation, Uveitis | Phase 1 | Completed | Quan Dong Nguyen | 10 | 2024-05-03 | 2026-11-02 |
| Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis Oftac: 0.05% tacrolimus ophthalmic emulsion - Non-Infectious Anterior Uveitis | Phase 1 / Phase 2 | Completed | BioNanoSim Ltd. | 18 | 2024-03-07 | 2026-10-13 |
| Minocycline for Chronic Autoimmune Uveitis minocycline - Minocycline, Uveitis | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 10 | 2021-12-01 | 2023-04-18 |
| Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Episcleral Celecoxib - Macula Edema, Radiation Retinopathy | Phase 1 | Unknown | Targeted Therapy Technologies, LLC | 3 | 2021-03-05 | 2023-11-24 |
| Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Episcleral Dexamethasone - Macular Edema, Radiation Retinopathy | Phase 1 | Unknown | Targeted Therapy Technologies, LLC | 2 | 2019-09-01 | 2023-11-24 |
| Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis pEYS606 - Non-infectious Uveitis | Phase 1 / Phase 2 | Completed | Eyevensys | 15 | 2017-04-04 | 2022-03-10 |
| Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis 8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops - Non-Infectious Anterior Uveitis | Phase 1 / Phase 2 | Completed | Aciont Inc | 44 | 2014-10-01 | 2017-04-27 |
| Safety and Preliminary Efficacy Study of V404 PDS in Uveitis V404 - Uveitis, Posterior, Uveitis, Intermediate | Phase 1 / Phase 2 | Terminated | Forsight Vision4 | 7 | 2014-04-01 | 2016-12-09 |
| Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Tocilizumab - Intermediate Uveitis, Posterior Uveitis | Phase 1 / Phase 2 | Unknown | University of Nebraska | 36 | 2013-03-01 | 2017-04-28 |
| Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose intravitreous administration of regulator T-cells - Uveitis | Phase 1 / Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 18 | 2013-03-01 | 2017-08-16 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
| Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Intravitreal Infliximab - Behçet's Disease, Uveitis | Phase 1 / Phase 2 | Completed | Cairo University | 20 | 2013-01-01 | 2015-12-03 |
| Ustekinumab for Active Sight-Threatening Uveitis Ustekinumab - Uveitis | Phase 1 / Phase 2 | Withdrawn | National Eye Institute (NEI) | 2012-07-03 | 2019-12-05 | |
| Anakinra for Behcet s Disease Anakinra - Autoimmune Connective Tissue Disorder, Immune System Diseases | Phase 1 / Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 6 | 2011-09-01 | 2017-05-12 |
| Topical Interferon Gamma for Macular Edema Secondary to Uveitis Interferon Gamma-1b - Anterior Uveitis, Uveitis | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2011-06-01 | 2012-10-08 |
Showing 20 of 43. Sign in to see all of them.
Macular Edema (12) · Uveitis, Intermediate (9) · Uveitis, Posterior (8) · Behcet Syndrome (6) · Inflammation (6) · Panuveitis (4) · Uveitis, Anterior (4) · Retinal Vein Occlusion (3) · Antiphospholipid Syndrome (2) · Choroidal Neovascularization (2) · Dermatomyositis (2) · Diabetic Retinopathy (2) · Epiretinal Membrane (2) · Pemphigoid, Bullous (2)
Uveal Diseases (43) · Eye Diseases (42) · Panuveitis (14) · Retinal Diseases (14) · Retinal Degeneration (12) · Cardiovascular Diseases (11) · Macular Degeneration (11) · Vascular Diseases (11) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Skin and Connective Tissue Diseases (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Skin Diseases (7)
Daclizumab (2) · Methotrexate (2) · Ranibizumab (2) · Sirolimus (2) · Triamcinolone (2) · Triamcinolone Acetonide (2) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Cell- and Tissue-Based Therapy (1) · Cyclosporine (1) · Diclofenac (1) · Infliximab (1) · Interferon-gamma (1) · Interleukin 1 Receptor Antagonist Protein (1) · Minocycline (1)
National Eye Institute (NEI) (13) · Chugai Pharmaceutical (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · Quan Dong Nguyen (2) · Targeted Therapy Technologies, LLC (2) · Aciont Inc (1) · Asociación para Evitar la Ceguera en México (1) · Assistance Publique - Hôpitaux de Paris (1) · BioNanoSim Ltd. (1) · Cairo University (1) · Clearside Biomedical, Inc. (1) · Eyevensys (1) · Forsight Vision4 (1) · Icahn School of Medicine at Mount Sinai (1) · Johns Hopkins University (1)
United States (32) · France (4) · Australia (3) · Austria (2) · Bulgaria (2) · Canada (2) · China (2) · Croatia (2) · Czechia (2) · Germany (2) · Hungary (2) · Iran (2) · Italy (2) · Japan (2) · Netherlands (2)
Hatice N Sen, M.D. (2) · Hatice Nida Sen, MD, MHSc (2) · Quan D Nguyen, MD, MSc (2) · Theodore Leng, MD (2) · Behrouz Nikbin, MD (1) · Dan Liang (1) · David G Callanan, MD (1) · Eric B Suhler, MD, MPH (1) · Farzin Forooghian, MD (1) · Fereydoun Davatchi, MD (1) · Hormoz Shams, MD (1)
PMID 19211094, PMID 21498606, PMID 21913066, PMID 22465364, PMID 23773637, PMID 25918559, PMID 27980877, PMID 28335798, PMID 30009894, PMID 33042579, PMID 36912792, PMID 39531369, PMID 42211725
2025 (1), R44EY014772 (1)